NCT00189943View on ClinicalTrials.gov

Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

90

Participants

Timeline

Start Date

April 30, 2001

Study Completion Date

July 31, 2003

Conditions

Smallpox

Interventions

BIOLOGICAL

MVA-BN

Trial Locations (1)

41061

PharmPlanNet Contract Research GmbH, Mönchengladbach

Sponsors

Lead Sponsor

Bavarian Nordic

All Listed Sponsors

lead

Bavarian Nordic

INDUSTRY

NCT00189943 - Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects | Biotech Hunter | Biotech Hunter